André S, Pieters R J, Vrasidas I, Kaltner H, Kuwabara I, Liu F T, Liskamp R M, Gabius H J
Institut für Physiologische Chemie, Tierärztliche Fakultät, Ludwig-Maximilians-Universität München, Veterinärstrasse 13, 80539 München, Germany.
Chembiochem. 2001 Nov 5;2(11):822-30. doi: 10.1002/1439-7633(20011105)2:11<822::AID-CBIC822>3.0.CO;2-W.
Galectins are mammalian carbohydrate-binding proteins that are involved in cell-cell and cell-matrix adhesion, cell migration, and growth regulation with relevance to inflammation and tumor spread. These important functions account for the interest to design suitable low molecular weight inhibitors that match the distinct modes of presentation of the carbohydrate recognition domains of the different galectin subfamilies. Using 3,5-di-(2-aminoethoxy)benzoic acid as the branching unit, wedgelike glycodendrimers with two, four, and eight lactose moieties (G1-G3) were synthesized. They were tested in solid-phase competition assays with lactose maxiclusters and various N-glycan branching profiles (miniclusters) as the matrix and also in cell assays. Prototype galectins-1 and -7, chimera-type galectin-3, a plant (AB)(2) toxin, and a lactose-binding immunoglobulin G fraction from human serum were the carbohydrate-binding targets. Potent inhibition and remarkable cluster effects were seen for the homodimeric galectin-1, especially in combination with biantennary N-glycans as the matrix. Remarkably, for the tetravalent G2 glycodendrimer, the inhibitory potency of each lactose unit reached a maximum value of 1667 relative to free lactose. In haemagglutination experiments as a model for cell adhesion, galectin-3 was markedly sensitive to increased sugar valency and a relative potency per lactose of 150 was reached. The spatial orientation of the carbohydrate recognition domains of the endogenous lectins and the branching pattern of the carbohydrates of the glycoprotein matrices used are both important factors in the design and synthesis of glycodendrimers with galectin-selective properties.
半乳糖凝集素是哺乳动物的碳水化合物结合蛋白,参与细胞间和细胞与基质的黏附、细胞迁移以及与炎症和肿瘤扩散相关的生长调节。这些重要功能引发了人们对设计合适的低分子量抑制剂的兴趣,这些抑制剂要与不同半乳糖凝集素亚家族碳水化合物识别结构域的不同呈现模式相匹配。以3,5-二-(2-氨基乙氧基)苯甲酸作为分支单元,合成了具有两个、四个和八个乳糖部分的楔形糖树状大分子(G1-G3)。它们在以乳糖最大簇和各种N-聚糖分支图谱(最小簇)为基质的固相竞争试验以及细胞试验中进行了测试。原型半乳糖凝集素-1和-7、嵌合型半乳糖凝集素-3、一种植物(AB)(2)毒素以及人血清中的乳糖结合免疫球蛋白G部分是碳水化合物结合靶点。对于同二聚体半乳糖凝集素-1,观察到了强效抑制和显著的簇效应,尤其是与双天线N-聚糖作为基质结合时。值得注意的是,对于四价G2糖树状大分子,每个乳糖单元的抑制效力相对于游离乳糖达到了1667的最大值。在作为细胞黏附模型的血细胞凝集实验中,半乳糖凝集素-3对糖价增加明显敏感,每个乳糖的相对效力达到了150。内源性凝集素的碳水化合物识别结构域的空间取向以及所使用的糖蛋白基质中碳水化合物的分支模式,都是设计和合成具有半乳糖凝集素选择性的糖树状大分子的重要因素。